Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

Abstract: The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts. The formulation can provide sustained release of antibody and antibody fragments, in particular, IgG. Antibody diffusivities can be decreased with increasing hydrogel nanofiber density, providing a means to control the release kinetics.

Abstract: A solventless method for forming a coating on a medical electrical lead is described. The method includes combining particles of a therapeutic agent with a polymeric material in a flowable form in the absence of a solvent to form a uniform suspension. A predetermined amount of the suspension is dispensed onto a portion of the lead and is then cured to form the therapeutic agent eluting layer. Additional layers such as a primer layer, fluoro-opaque layer and/or a topcoat layer can be formed using the solventless method. Employing a solventless method may avoid contraction of the layer being formed due to solvent evaporation during the curing process, and may facilitate greater control over the thickness of the therapeutic agent eluting coating.

Abstract: In order to provide an improved powder coating process using gelatin particles for the production of coatings or shaped bodies based on gelatin, it is proposed that the gelatin particles are produced by drying an aqueous gelatin solution, wherein the gelatin does not pass through a gel state before or during the drying.

Abstract: A dosage form which is, in particular, sheet-like and rapidly disintegrating or soluble in an aqueous environment for rapid release of active ingredients in the oral cavity, in body orifices or in body cavities, where the dosage form comprises a matrix which comprises one or more water -soluble polymers as base substances, and comprises at least one active ingredient, is characterized in that the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ in terms of the state of aggregation from the matrix.

Abstract: Disclosed is a method for preparing ajoene including: (a) obtaining garlic pulp or garlic extract from garlic; (b) mixing the garlic pulp or garlic extract with animal lipid to form a reaction mixture; and (c) heating the reaction mixture to obtain ajoene. The ajoene prepared according to the present disclosure may be encapsulated with gelatin. According to the present disclosure, ajoene can be prepared with a yield 2 times or more than that of the existing methods. Thus, ajoene can be provided as active ingredient for foods and medicines more cost-effectively. Also, the production protocol according to the present disclosure is suitable for large-scale production of ajoene.

Abstract: The present invention provides materials and methods that can serve as a prosthetic and/or, for tissue engineer applications, as a supporting matrix in the stabilization of the myocardium.

Abstract: The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.

Abstract: A stable soft gel dosage form for acetylsalicylic acid (ASA), aspirin, is provided wherein soft gel capsules containing the ASA can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over the period of six months. A suspension of ASA in a monoglyceride component comprising more than about 50% glyceryl monooleate is packaged in a soft gelatin capsule, which can be substantially free of other components. The ASA in this composition is resistant to hydrolysis from water contained within the soft gelatin matrix or diffusing through the matrix. Methods of preparation and methods of use are also provided.

Abstract: A capsule with good disintegration properties that can quickly display its content's efficacy as well as a method for preparing the same are provided. More specifically, provided is a capsule comprising a shell comprising low-substituted cellulose ether. Also, provided is a method for preparing a hard capsule comprising the low-substituted cellulose ether comprising a step of covering a pin for forming the hard capsule with the low-substituted cellulose ether by immersing the pin in an alkaline solution of the low-substituted cellulose ether; a step of forming the low-substituted cellulose on a surface of the pin into a gel by further immersing the covered pin in an aqueous acid solution; a step of washing by immersing the pin whose surface has been covered with the gel in water; and a step of drying.

Abstract: A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.

Abstract: A dosage form which is, in particular, sheet-like and rapidly disintegrating or soluble in an aqueous environment for rapid release of active ingredients in the oral cavity, in body orifices or in body cavities, where the dosage form comprises a matrix which comprises one or more water-soluble polymers as base substances, and comprises at least one active ingredient, is characterized in that the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ in terms of the state of aggregation from the matrix.

Abstract: The present invention relates to a new coating composition and especially a new coating composition to be used with a specific coating device for providing an even, thin and enclosing coating on tablets, capsules or pills of different sizes and shapes in order to improve the taste and the swallowing characteristics of the tablets, capsules or pills.

Abstract: The invention relates to the use of a coating composition for application to a solid veterinary pharmaceutical composition for oral administration for the prevention and/or treatment of cardiac insufficiency in animals, by a method of film coating comprising a powder appetizing material, a binder and a solvent. The invention further relates to a coating method by film coating of solid veterinary pharmaceutical compositions for oral administration for the prevention and/or treatment of cardiac insufficiency in animals and appetizing medicaments for animals comprising a solid veterinary pharmaceutical composition for oral administration for the prevention and/or treatment of cardiac insufficiency in animals made from pimobendan and an appetizing coating arranged around said composition comprising an appetizing material and a binder.

Abstract: Methods and compositions for producing hydrogel capsules enveloped with at least one coating layer is disclosed. The coating formulations deposited on the surface of the capsules can improve the physical integrity and the water-retention properties of the alginate beads. The coating formulations can be sequentially applied in various combinations to obtain desirable properties, such as improved physical integrity, mechanical strength, and low permeability, that can extend the shelf-life of the capsules when incorporated into various consumer products.

Abstract: Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.

Abstract: In order to provide an improved powder coating process using gelatin particles for the production of coatings or shaped bodies based on gelatin, it is proposed that the gelatin particles are produced by drying an aqueous gelatin solution, wherein the gelatin does not pass through a gel state before or during the drying.

Abstract: Small scale and nanoscopic identification features can be fabricated for pharmaceutical capsules. A composition comprising a capsule component, wherein the capsule component comprises a gelled pharmaceutical capsule material and at least one surface, wherein the at least one surface comprises at least one integral feature with a lateral dimension smaller than about 100 microns, or less than one micron. Methods of making the same are described by gelation with heating or cooling. The compositions and methods can be used for anti-counterfeiting.

Abstract: A new class of biosensors and methods for making and using same are disclosed. The biosensors are multi-layered membrane composites, where at least one layer is prepared by the layer-by-layer process and at least one layer is responsive to changes is a property of a biological system such as changes in the concentration of an atom, ion, molecule or molecular assembly. Because the biosensors are multi-layered, a single biosensor is capable monitor a number of different properties of a biological system simultaneously. The biosensors are monitored by systems that impinge an excitation waveform on the biosensors and analyze a reflected and/or a transmitted resultant waveform. Additionally, the biosensors can be associated with field activated electronic components so that implantable, self-contained analytical devices can be constructed and monitored by field generators, where data is transmitted to an analyzer after field activation.

Abstract: A method for producing an oral medication includes dispensing a structural material, the structural material including one of a polymer or a gelatin, curing the structural material, and dispensing a jettable pharmaceutical solution onto the cured structural material.

Abstract: A biomaterial comprising a porous biocompatible structure and a demineralized bone extract coated onto into the pores of the biocompatible structure are provided. The biomaterial may also comprise a demineralized bone gelatin where the gelatin may be coated over the extract coating or mixed with the extract coating before being applied to the biocompatible structure. Methods for making the biomaterial are also provided.

Abstract: A process for enrobing a core, such as a tablet core, uses a coating that is made of a patterned film having portions that are visually distinct (e.g, differently colored) from one another and having a transition line segment between these visually distinct portions. At least a portion of an outer surface of the core is covered with the film, such that the transition line segment forms a substantially continuous transition line on the coating and such that a film seam is formed which is different from the transition line. Alternatively, the coating is formed from two such patterned films, in which case the outer surface of the core is covered with the two films such that the two transition line segments cooperate to form a substantially continuous transition line on the coating and a film seam is formed which is different from the transition line.

Abstract: A semiconductor nanoparticle for use in analysis of biological samples is described. This semiconductor nanoparticle is composed of an aminodextran which is bound to at least one nanoparticle of the formula (X Y)n wherein X is selected from the group comprising Cd2+, Hg2+, and Zn2+ and combinations thereof, and Y is selected from the group comprising S2−, Se2− and Te2− and combinations thereof; and n=approximately 50 to 1000. Also provided are methods of making these semiconductor nanoparticles and methods of making conjugates composed of these semiconductor nanoparticles linked to ligands. Also described are uses for the conjugates in a variety of biological assays.

Abstract: The invention relates to a process for producing coated solid dosage forms by forming a plastic mixture from at least one thermoplastic physiologically tolerated polymeric binder and at least one active ingredient and extruding the plastic mixture, wherein the extrudate is subsequently treated with at least one liquid or vaporized coating agent, and the coated extrudate is shaped to the required dosage form.

Abstract: A semiconductor nanoparticle for use in analysis of biological samples is described. This semiconductor nanoparticle is composed of an aminodextran which is bound to at least one nanoparticle of the formula (X Y)n wherein X is selected from the group comprising Cd2+, Hg2+, and Zn2+ and combinations thereof; and Y is selected from the group comprising S2−, Se2− and Te2− and combinations thereof; and n=approximately 50 to 1000. Also provided are methods of making these semiconductor nanoparticles and methods of making conjugates composed of these semiconductor nanoparticles linked to ligands. Also described are uses for the conjugates in a variety of biological assays.